ClinicalTrials.gg
Not yet recruitingNCT04239859Updated Nov 25, 2022

Outcomes With Treatment and Withdraw of Secukinumab in Patients With Plaque Psoriasis

A Phase 4 interventional study of secukinumab and Methotrexate in Plaque Psoriasis, sponsored by Singapore General Hospital. Not yet recruiting at 1 site in Singapore. Open to participants aged 22 Years to 90 Years. Per ClinicalTrials.gov, last updated 2022-11-25.

Sponsored by Singapore General Hospital · Phase 4, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
22 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies testing secukinumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. secukinumab · Psoriasis.

Planned enrollment
39th of 54
40 · median 124
Started
2024
with 1 other
Phase 4
17 of 54
4 open now
Registered
42nd of 54
by date
Lead sponsor
1 of 54
Singapore General Hospital

Among the 54 studies testing secukinumab in Psoriasis, this one is the 39th largest by planned enrollment, is one of 2 that started in 2024, is one of 17 in phase 4, and was the 42nd registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 54 studies testing secukinumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About secukinumab

secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.

This study: 22 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing secukinumab in Psoriasis, or all of them as a file.
02

Study summary

Psoriasis (PsO) is a systemic immune disease that affect 2-4% of the population worldwide. PsO causes tremendous burden in terms of quality of life, psychological impact, disability and work productivity of affected individuals. PsO is associated with an increased risk of cardiovascular morbidities and mortality in the long term. Up to 30% of PsO patients develop psoriatic arthritis (PsA) over time causing joint deformities and further disabilities. Majority of patients with PsA developed PsO first, and arthritis develop 5-10 years after. PsA and PsO are increasingly recognized as two entities under the umbrella of psoriatic diseases.

Advances in biological treatments have greatly improved the prognosis of patients with PsO. Remarkable efficacies have been demonstrated for patients with moderate to severe PsO in randomized controlled trials (RCTs). However, the high cost of biological treatment is one of the major barriers to its prescription and many patients may have limited access to these treatments.

The best treatment strategy for PsO that takes into account efficacy and cost effectiveness is unknown. For instance, whether some PsO patients can stop biological treatment and be treated with non-biologic medications upon relapse, which may enhance cost effectiveness of treatment. Preliminary studies have shown that some PsO patients were able to maintain good control of disease without medications after biologics withdrawal. The patho-immunological mechanisms behind long term remission after drug withdrawal is poorly understood. Better understanding of these mechanisms in maintaining remission and relapses will advance the development of biomarkers that eventually guide development of best treatment strategies for PsO.

Secukinumab targets interleukin (IL)-17a and is highly efficacious in the treatment of plague PsO with a favorable safety profile. Some patients may have the response maintained after withdrawal of secukinumab. With the proven efficacies, sustainability after withdrawal and safety profile, secukinumab could be a choice of initial treatment for patients with moderate to severe PsO. Secukinumab has been recommended as first line treatment for selected patients with moderate to severe PsO by the American Academy of Dermatology and the European S3 guidelines. However, the use of biologics as first line is limited by cost issue. Overall, real-life data on biologic treatment for moderate to severe PsO is scanty.

Read the detailed description

First, the investigators hypothesize that a proportion of participants with moderate to severe PsO may sustain good outcomes when a short course of secukinumab is withdrawn.

Second, the investigators hypothesize that they can identify the perturbations in the architecture of the immunome which are pathogenic, and to discriminate such perturbations based on treatment and clinical responses, thus distilling therapeutics and diagnostics signatures.

Therefore, the objectives of this study are as follow:

Specific aim 1: To describe the clinical course, sustained good outcomes, relapse rate, time to relapse and quality of life in PsO participants who stopped a 6-month short course treatment of secukinumab, till the end of 2-years.

Specific aim 2: To identify the genomic and immunomics signatures in skin biopsies and blood in PsO participants who has good outcomes (PASI 75) at 6 months, comparing treatment vs pragmatic control.

Specific aim 3: To identify the genomic and immunomics signatures in skin biopsies and blood in PsO participants who sustained good outcomes at 1 year after stopping secukinumab, compared to those relapsed.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
22 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (>21-year-old).
  • Diagnosed by dermatologist as plague-type PsO.
  • Having moderate to severe plague-type PsO as defined by the following:
  • Psoriasis Area and Severity Index (PASI) ≥12/72,
  • And, investigator Global Assessment Score (IGA) ≥3,
  • And, PsO involving body surface area involvement (BSA) ≥10%
  • And Candidate for phototherapy and/or systemic therapy
  • Topical up to moderate potencies are allowed
  • Able to provide .

Exclusion criteria

Exclusion Criteria:

  • Forms of PsO other than plaque-type.
  • Evidence of skin conditions at the time of the screening visit (e.g. eczema) that would interfere with evaluation of the effect of the product on PsO.
  • Evidence of active tuberculosis or other active infections (like /B), ; active or known use of other drugs (eg. AIDS, rheumatoid arthritis, organ rejection etc) at the screening visit.
  • Previous exposure to any systemic immunosuppressants (eg. methotrexate) or phototherapy
  • History or current signs of a severe, progressive, or uncontrolled renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances.
  • Having current or history of malignancy, except non-melanoma skin cancer, within the previous 5 years that have been adequately treated.
  • History of inflammatory bowel disease.
  • Pregnancy or lactating mothers.
  • As treatment regimen is different, participants with evidence of PsA will be excl
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Secukinumab

    Participants will be offered secukinumab as first-line systemic treatment for moderate to severe PsO. The indication for secukinumab will be equivalent to current registered indications. Standard dose of subcutaneous secukinumab for moderate to severe PsO will be given at 300 mg at weeks 0, 1, 2, 3, and 4, then monthly thereafter, for a total duration of 6 months. secukinumab will be withdrawn after 6 months. For some participants, there may be relapse of PsO. Relapses will be managed as per standard care.

    Biological: secukinumab

  • Active comparator
    Standard Care

    The management of PsO in the control arm will be the same as that in the standard care. The standard care for moderate to severe PsO in Singapore is to start either phototherapy, methotrexate, acitretin or cyclosporin A.

    Drug: Methotrexate · Drug: Cyclosporin A · Drug: Acitretin

Interventions

  • Biologicalsecukinumab

    Secukinumab for 6 months, given at weeks 0, 1, 2, 3 and 4, then monthly till 6 months. 300mg per administration, subcutaneously.

  • Oral tablet up to 15mg per week

  • DrugCyclosporineStudies of CyclosporineCyclosporine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral capsule up to 200mg per day

  • Oral capsule up to 25mg per day

06

What researchers measure

Primary outcomes

  1. Proportion of secukinumab treated PsO participants free of relapse after secukinumab withdrawal

    The investigators will describe the proportion of secukinumab treated PsO participants free of relapse at 12 months after secukinumab withdrawal.

    Time frame: 12 months from secukinumab withdrawal or 18 months from baseline

Secondary outcomes

  1. Proportion of secukinumab treated PsO participants free of relapse after secukinumab withdrawal

    The investigators will describe the proportion of secukinumab treated PsO participants free of relapse at 15, 18, and 24 months after secukinumab withdrawal.

    Time frame: 15, 18, and 24 months from secukinumab withdrawal or 21, 24, and 30 months from baseline

  2. Proportion of participants achieving PASI 50

    Psoriasis is assessed by using the Psoriasis Area Severity Index (PASI) that measures the severity (intensity of redness, thickness and scaling is assessed as none (0), mild (1), moderate (2), severe (3) or very severe (4)) and percentage of affected area in four regions of the body (head and neck, upper limbs, trunk, lower limbs, expressed as nil (0), 1-9% (1), 10-29% (2), 30-49% (3), 50-69% (4), 70-89% (5) or 90-100% (6)). The score ranges from 0 (no psoriasis) to 72 (severe psoriasis). Percentage of improvement of PASI at 3 month and 6 month time points will be calculated from baseline. PASI 50 indicates a 50% improvement of PASI scores.

    Time frame: 3 months and 6 months

  3. Proportion of participants achieving PASI 75

    Psoriasis is assessed by using the Psoriasis Area Severity Index (PASI) that measures the severity (intensity of redness, thickness and scaling is assessed as none (0), mild (1), moderate (2), severe (3) or very severe (4)) and percentage of affected area in four regions of the body (head and neck, upper limbs, trunk, lower limbs, expressed as nil (0), 1-9% (1), 10-29% (2), 30-49% (3), 50-69% (4), 70-89% (5) or 90-100% (6)). The score ranges from 0 (no psoriasis) to 72 (severe psoriasis). Percentage of improvement of PASI at 3 month and 6 month time points will be calculated from baseline. PASI 75 indicates a 75% improvement of PASI scores.

    Time frame: 3 months and 6 months

  4. Proportion of participants achieving PASI 90

    Psoriasis is assessed by using the Psoriasis Area Severity Index (PASI) that measures the severity (intensity of redness, thickness and scaling is assessed as none (0), mild (1), moderate (2), severe (3) or very severe (4)) and percentage of affected area in four regions of the body (head and neck, upper limbs, trunk, lower limbs, expressed as nil (0), 1-9% (1), 10-29% (2), 30-49% (3), 50-69% (4), 70-89% (5) or 90-100% (6)). The score ranges from 0 (no psoriasis) to 72 (severe psoriasis). Percentage of improvement of PASI at 3 month and 6 month time points will be calculated from baseline. PASI 90 indicates a 90% improvement of PASI scores.

    Time frame: 3 months and 6 months

  5. Proportion of participants achieving clearance

    Psoriasis is assessed by using the Psoriasis Area Severity Index (PASI) that measures the severity (intensity of redness, thickness and scaling is assessed as none (0), mild (1), moderate (2), severe (3) or very severe (4)) and percentage of affected area in four regions of the body (head and neck, upper limbs, trunk, lower limbs, expressed as nil (0), 1-9% (1), 10-29% (2), 30-49% (3), 50-69% (4), 70-89% (5) or 90-100% (6)). The score ranges from 0 (no psoriasis) to 72 (severe psoriasis). Percentage of improvement of PASI at 3 month and 6 month time points will be calculated from baseline. Clearance indicates a 100% improvement of PASI scores.

    Time frame: 3 months and 6 months

  6. Quality of life 1 (EuroQoL-5D-5L)

    In all participants (both secukinumab treated and standard care) the investigators will describe the following: Every 3-6 monthly till end of 30 months, investigators will evaluate the change scores of Quality of Life (EQ5D-5L). It consists of the EQ-5D-5L descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises five dimensions. Each dimension is measured on a scale of 1-5, with '1' indicating no problem, '2' indicating slight problems, '3' indicating moderate problems, '4' indicating severe problems, and '5' indicating unable to/extreme problems. The highest and the lowest scores for both EQ-5D-5L indices were 1.00 (best imaginable health) and -0.769 respectively; where negative values are valued as worse than dead. EQ VAS records the patient's self-rated health on a vertical visual analogue scale from 0-100 with '0' indicating worst health one can imagine and '100' indicating best health one can imagine.

    Time frame: 3, 6, 9, 12, 15, 18, 24 and 30 months

  7. Quality of life 2 (Dermatology Life Quality Index - DLQI)

    In all participants (both secukinumab treated and standard care) the investigators will describe the following: - Questionnaires on health status and quality of life every 3-6 monthly till end of 30 months. The investigators will evaluate the change scores of Dermatology Life Quality Index (DLQI) at various time points from baseline. DLQI is measured on a scale of 0-3 or not relevant, with '0' indicating not relevant or not at all, '1' indicating a little, '2' indicating a lot, '3' indicating very much. The final score ranges from 0 (minimal effect on quality of life) to 30 (maximum effect on quality of life).

    Time frame: 3, 6, 9, 12, 15, 18, 24 and 30 months

  8. Quality of life 3 (Hospital Anxiety and Depression Scale - HADS)

    In all participants (both secukinumab treated and standard care) the investigators will describe the following: - Questionnaires on health status and quality of life every 3-6 monthly till end of 30 months. The investigators will evaluate the change scores of Hospital Anxiety and Depression Scale (HADS) at various time points from baseline. HADS is a 14 item scale with 7 of the items related to anxiety and the other 7 related to depression. Each item on the questionnaire is scored from 0-3, resulting in anxiety and depression scores each of 0 (no anxiety/depression) to 21 (severe anxiety/depression).

    Time frame: 3, 6, 9, 12, 15, 18, 24 and 30 months

  9. Patient Global Assessment

    In all participants (both secukinumab treated and standard care) the investigators will describe the following: - Questionnaires on health status and quality of life every 3-6 monthly till end of 30 months. The investigators will evaluate the change scores of Patient Global Assessment (0-10) at various time points from baseline, with higher scores meaning worse outcome.

    Time frame: 3, 6, 9, 12, 15, 18, 24 and 30 months

  10. Patient Acceptable Symptom State (PASS)

    In all participants (both secukinumab treated and standard care) the investigators will describe the following: - Questionnaires on health status and quality of life every 3-6 monthly till end of 30 months. The investigators will evaluate the proportion of patient defined acceptable state (acceptable/unacceptable) and whether the symptoms are worse than usual (yes/no) at various time points from baseline.

    Time frame: 3, 6, 9, 12, 15, 18, 24 and 30 months

  11. Proportion of participants in secukinumab treatment arm maintaining PASI 50 after secukinumab withdrawal

    For participants in the secukinumab treatment arm, the investigators describe the following in additional: - The proportion of participants maintaining PASI 50 at 3, 6, 12, 18 and 24 months after stopping secukinumab treatment

    Time frame: 9, 12, 18, 24 and 30 months from baseline

  12. Proportion of participants in secukinumab treatment arm maintaining PASI 75 after secukinumab withdrawal

    For participants in the secukinumab treatment arm, the investigators describe the following in additional: - The proportion of participants maintaining PASI 75 at 3, 6, 12, 18 and 24 months after stopping secukinumab treatment

    Time frame: 9, 12, 18, 24 and 30 months from baseline

  13. Proportion of participants in secukinumab treatment arm maintaining PASI 90 after secukinumab withdrawal

    For participants in the secukinumab treatment arm, the investigators describe the following in additional: - The proportion of participants maintaining PASI 90 at 3, 6, 12, 18 and 24 months after stopping secukinumab treatment

    Time frame: 9, 12, 18, 24 and 30 months from baseline

  14. Proportion of participants in secukinumab treatment arm maintaining clearance after secukinumab withdrawal

    For participants in the secukinumab treatment arm, the investigators describe the following in additional: - The proportion of participants maintaining PASI clearance at 3, 6, 12, 18 and 24 months after stopping secukinumab treatment

    Time frame: 9, 12, 18, 24 and 30 months from baseline

  15. Proportion of participants in secukinumab treatment arm flaring after secukinumab withdrawal

    For participants in the secukinumab treatment arm, the investigators describe the following in additional: - The proportion of participants who flare (defined as losing the PASI50 response) at 3, 6, 12, 18 and 24 months after stopping secukinumab treatment

    Time frame: 9, 12, 18, 24 and 30 months from baseline

  16. Histological changes in the skin biopsies of participants in secukinumab treatment arm who relapsed after secukinumab withdrawal (or at 18 months if no relapse)

    For participants in the secukinumab treatment arm, the investigators will evaluate the following outcomes at relapse (or at 12 months after stopping secukinumab if no relapse): - Histological sections of morphologically psoriasis (lesional) and morphologically no psoriasis (nonlesional) skin biopsies. Skin biopsies at relapse will be scored for the degree of histological improvement compared to that participant's disease at 6 months on a five point scale; -1 (worse) to +3 (excellent).

    Time frame: Baseline, 6 months, at relapse (or 18 months if no relapse)

  17. Skin genomic profiles in the skin biopsies of participants in secukinumab treatment arm who relapsed after secukinumab withdrawal (or at 18 months if no relapse)

    For participants in the secukinumab treatment arm, the investigators will evaluate the following outcomes at relapse (or at 12 months after stopping secukinumab if no relapse): - Whole RNA genome transcriptome of the skin biopsies will be studied. The change in transcriptomes at relapse compared to 6-month will be evaluated.

    Time frame: Baseline, 6 months, at relapse (or 18 months if no relapse)

  18. Peripheral blood immunome profiles of participants in secukinumab treatment arm who relapsed after secukinumab withdrawal (or at 18 months if no relapse)

    For participants in the secukinumab treatment arm, the investigators will evaluate the following outcomes at relapse (or at 12 months after stopping secukinumab if no relapse): * The B-cell and T-cell subtypes in the peripheral blood will be evaluated using mass cytometry, and compared to that of baseline and 6 months. * The investigators will evaluate the change in B-cell and T-cell Subtypes at relapse compared to baseline and 6 months.

    Time frame: Baseline, 6 months, at relapse (or 18 months if no relapse)

  19. Histological changes in the skin biopsies

    In all participants, the investigators will evaluate the skin genomic profiles that differentiate between secukinumab versus standard care control arms. - Histological sections of morphologically psoriasis (lesional) and morphologically no psoriasis (non lesional) skin biopsies at baseline and 6 months will be examined. Skin biopsies at 6 month will be scored for the degree of histological improvement compared to that participant's baseline disease on a five point scale; -1 (worse) to +3 (excellent).

    Time frame: Baseline and 6 months

  20. Skin genomic profiles

    In all participants, the investigators will evaluate the skin genomic profiles that differentiate between secukinumab versus standard care control arms. - Whole RNA genome transcriptome of the skin biopsies will be studied. The change in transcriptomes at 6 months compared to baseline will be evaluated.

    Time frame: Baseline and 6 months

  21. Peripheral blood immunome profiles

    In all participants, the investigators will evaluate the blood immunome profiles that differentiate between secukinumab versus standard care control arms. - The B-cell and T-cell subtypes in the peripheral blood of participants in both secukinumab and standard care arms will be evaluated using mass cytometry. - The investigators will evaluate the change in B-cell and T-cell subtypes at 6 months from baseline for all participants

    Time frame: Baseline and 6 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2024; primary completion for Dec 2027, 47 months later.

Of 75 non-industry phase 4 interventional studies under Psoriasis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 47 months is above that.

Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2019
First posted
Jan 27, 2020
StartEst.
Jan 2024
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Nov 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04239859
Collaborators
Translational Immunology Institute
Responsible party
Sponsor
First posted
Jan 27, 2020
Start date
Jan 2024 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 25, 2022

Study contacts

Ying Ying Leung, MD
Contact
katy.leung.y.y@singhealth.com.sg
+65 63265276
Cynthia Ong, Bachelor
Contact
cynthia.ong.s.q@singhealth.com.sg
+65 65762609
Ying Ying Leung, MD
principal investigator · Singapore General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion